m-EASIX (better than EASIX) predicts severe CAR T-cell toxicities, worse overall survival, and discriminates cytokine release syndrome from sepsis.


Por: Moreno-Castaño AB, Fernández S, Brillembourg H, Iraola G, Moreno DF, Ventosa-Capell H, Martinez-Sanchez J, De Moner B, Molina P, Ramos A, Palomo M, Gómez-Ramírez P, Ortiz-Maldonado V, Martínez-Cibrián N, Delgado J, Oliver-Caldés A, Fernández de Larrea C, Salas MQ, Urbano Á, Téllez A, Nicolás JM, Juan M, González-Navarro A, Penack O, Escolar G, Carreras E, Fernández-Avilés F, Castro P and Diaz-Ricart M

Publicada: 7 ene 2026 Ahead of Print: 7 ene 2026
Resumen:
BACKGROUND: Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) are life-threatening complications that often arise after CAR T-cell immunotherapy. Endothelial dysfunction is believed to play a central role in their development, leading to the interest in biomarker-based tools for diagnosis and differentiating these toxicities from sepsis. This study aimed to evaluate the Endothelial Activation Stress Index (EASIX) and its modified version (m-EASIX, which replaces creatinine with C-reactive protein [CRP] (mg/dL)) as early predictors of severe CRS and ICANS, as well as tools to distinguish CRS from sepsis. METHODS: One hundred and nineteen patients treated with CAR T-cell therapy for CD19-positive hematologic malignancies (n=94) or multiple myeloma (n=23) were included. EASIX and m-EASIX scores were measured at various time points: before CAR T-cell infusion, 24-48 hours post-infusion, at CRS or ICANS onset, and after treatment for each toxicity. A comparator group of 129 sepsis patients, including 86 with hematologic malignancies, was also analyzed. RESULTS: Both EASIX and m-EASIX correlated with biomarkers of endotheliopathy, with m-EASIX showing stronger predictive power for severe toxicities and ICU admission. Higher EASIX and m-EASIX values at early time points were associated with worse overall survival (OS). Furthermore, m-EASIX accurately distinguished CRS from sepsis at symptom onset. CONCLUSIONS: m-EASIX is a practical and accessible tool for the early prediction of severe CAR T-cell-related toxicities, risk stratification, and differential diagnosis from sepsis, offering potential to guide clinical decision-making and early intervention.

Filiaciones:
Moreno-Castaño AB:
 Hemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre Diagnòstic Biomèdic (CDB), Clínic Barcelona, Barcelona, Spain

 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

 Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain

Fernández S:
 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

 Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain

 Medical Intensive Care Unit, Clínic Barcelona, Barcelona, Spain

Brillembourg H:
 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

Iraola G:
 Medical Intensive Care Unit, Clínic Barcelona, Barcelona, Spain

Moreno DF:
 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

Ventosa-Capell H:
 Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain

 Medical Intensive Care Unit, Clínic Barcelona, Barcelona, Spain

Martinez-Sanchez J:
 Hemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre Diagnòstic Biomèdic (CDB), Clínic Barcelona, Barcelona, Spain

 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

:
 Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain

 Josep Carreras Leukaemia Research Institute (Campus Clinic), Barcelona, Spain

 Hemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre Diagnòstic Biomèdic (CDB), Clínic Barcelona, Barcelona, Spain

Molina P:
 Hemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre Diagnòstic Biomèdic (CDB), Clínic Barcelona, Barcelona, Spain

Ramos A:
 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

Palomo M:
 Hematology External Quality Assessment Laboratory, Centre de Diagnòstic Biomèdic, Clínic Barcelona, Barcelona, Spain

Gómez-Ramírez P:
 Hemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre Diagnòstic Biomèdic (CDB), Clínic Barcelona, Barcelona, Spain

Ortiz-Maldonado V:
 Hematology Department, Institut del Càncer i Malalties de la Sang (ICAMS), IDIBAPS, Hospital Clínic de Barcelona, Barcelona, Spain

Martínez-Cibrián N:
 Hematology Department, Institut del Càncer i Malalties de la Sang (ICAMS), IDIBAPS, Hospital Clínic de Barcelona, Barcelona, Spain

Delgado J:
 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

 Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain

 Hematology Department, Institut del Càncer i Malalties de la Sang (ICAMS), IDIBAPS, Hospital Clínic de Barcelona, Barcelona, Spain

Oliver-Caldés A:
 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

 Hematology Department, Institut del Càncer i Malalties de la Sang (ICAMS), IDIBAPS, Hospital Clínic de Barcelona, Barcelona, Spain

Fernández de Larrea C:
 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

 Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain

 Hematology Department, Institut del Càncer i Malalties de la Sang (ICAMS), IDIBAPS, Hospital Clínic de Barcelona, Barcelona, Spain

Salas MQ:
 Hematology Department, Institut del Càncer i Malalties de la Sang (ICAMS), IDIBAPS, Hospital Clínic de Barcelona, Barcelona, Spain

Urbano Á:
 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

 Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain

 Hematology Department, Institut del Càncer i Malalties de la Sang (ICAMS), IDIBAPS, Hospital Clínic de Barcelona, Barcelona, Spain

Téllez A:
 Medical Intensive Care Unit, Clínic Barcelona, Barcelona, Spain

Nicolás JM:
 Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain

 Medical Intensive Care Unit, Clínic Barcelona, Barcelona, Spain

Juan M:
 Immunology Department, Centre de Diagnòstic Biomèdic, Clínic Barcelona, Barcelona, Spain

González-Navarro A:
 Immunology Department, Centre de Diagnòstic Biomèdic, Clínic Barcelona, Barcelona, Spain

Penack O:
 Charité Hospital, Berlin, Germany

Escolar G:
 Hemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre Diagnòstic Biomèdic (CDB), Clínic Barcelona, Barcelona, Spain

 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

 Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain

Carreras E:
 Josep Carreras Leukaemia Research Institute (Campus Clinic), Barcelona, Spain

Fernández-Avilés F:
 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

 Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain

 Hematology Department, Institut del Càncer i Malalties de la Sang (ICAMS), IDIBAPS, Hospital Clínic de Barcelona, Barcelona, Spain

Castro P:
 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

 Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain

 Medical Intensive Care Unit, Clínic Barcelona, Barcelona, Spain

Diaz-Ricart M:
 Hemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre Diagnòstic Biomèdic (CDB), Clínic Barcelona, Barcelona, Spain

 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

 Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
ISSN: 16643224





Frontiers in Immunology
Editorial
Frontiers Media S.A., AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND, Suiza
Tipo de documento: Article
Volumen: 16 Número:
Páginas: 1664788-1664788
WOS Id: 001665884100001
ID de PubMed: 41573561
imagen Green Submitted, gold

MÉTRICAS